An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …

New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear
in several European countries for treatment of asthma. This review examines currently …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

In the last two decades several significant changes have been proposed in the receptor
theory that describes how ligands can interact with G protein‐coupled receptors (GPCRs) …

Background. Asthma is characterized by hyperresponsiveness of the airways to
bronchoconstrictive stimuli. Long-acting β2-adrenoceptor agonists have been introduced as …

Introduction Asthma, a heterogeneous disease, is characterized by chronic airway
inflammation and hyperreactivity. β2-adrenoreceptor agonists (β2-agonists) remain pivotal …

Salmeterol and formoterol are both long-acting β 2-adrenoceptor agonists (β 2-agonists).
They both provide excellent bronchodilating and bronchoprotective effects in patients with …

All guidelines recommend short‐acting inhaled β2‐adrenoceptor agonists as the first‐line
drugs in acute asthma attacks and inhaled corticosteroids as the drugs of choice when …

β2-adrenoceptor agonists are the mainstay for the acute symptomatic treatment of asthma
and provide effective bronchoprotection to a wide range of bronchoconstrictor agents …

Long-acting b-agonists (LABAs) were originally approved for the treatment of asthma in the
early 1990s. Despite nearly 20 years of experience with these medications, there is a storm …